Ticagrelor or Aspirin After Coronary Artery Bypass in Patients With Chronic Kidney Disease

TiCAB Investigators, Sigrid E. Sandner*, Heribert Schunkert, Adnan Kastrati, Milan Milojevic, Andreas Böning, Daniel Zimpfer, Stephan Zellmer, Dominik Wiedemann, Günther Laufer, Moritz von Scheidt

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Background: The optimal antiplatelet therapy for patients with chronic kidney disease (CKD) undergoing coronary artery bypass graft surgery remains unknown. Methods: This post hoc analysis of the Ticagrelor in Coronary Artery Bypass (TiCAB) trial examined the efficacy and safety of ticagrelor vs aspirin in patients with and patients without CKD. The primary endpoint was major adverse cardiac and cerebrovascular events (MACCE), namely, the composite of cardiovascular death, stroke, myocardial infarction, or revascularization at 1 year after coronary artery bypass graft surgery. Secondary endpoints included individual components of the primary endpoint, all-cause death, and major bleeding. Results: Chronic kidney disease was present in 276 of 1843 randomized patients (15%). Patients with CKD vs patients without CKD had higher 1-year rates of MACCE (13% vs 8.3%, hazard ratio [HR] 1.63; 95% confidence interval [CI], 1.12 to 2.39; P =.01) and major bleeding (5.6% vs 3.1%, HR 1.84; 95% CI, 1.03 to 3.28; P =.04). The 1-year rate of MACCE was increased with ticagrelor vs aspirin in patients with CKD (18.2% vs 8.9%, HR 2.15; 95% CI, 1.08 to 4.30; P =.03), but not in patients without CKD (8.5% vs 8.1%, HR 1.05; 95% CI, 0.74 to 1.49; P =.79; Pinteraction =.067). There was no difference in the 1-year rate of major bleeding with ticagrelor vs aspirin in patients with CKD (6.6% vs 4.7%, HR 1.44; 95% CI, 0.52 to 3.97; P =.48) and patients without CKD (3.3% vs 2.9%, HR 1.14; 95% CI, 0.64 to 2.01; P =.65). Conclusions: Among patients with CKD and coronary artery bypass graft surgery, those who received ticagrelor had a higher incidence of MACCE but a similar incidence of major bleeding compared with those who received aspirin.

Original languageEnglish
Pages (from-to)554-562
Number of pages9
JournalAnnals of Thoracic Surgery
Volume113
Issue number2
Early online date2 Apr 2021
DOIs
Publication statusPublished - 1 Feb 2022

Bibliographical note

Funding Information:
The TiCAB trial was sponsored by Deutsches Herzzentrum M?nchen, Germany. Financial support for the trial was provided by AstraZeneca. Dr von Scheidt received funding from the Clinician Scientist Excellence Program of the German Center for Cardiovascular Research (DZHK), the German Society of Cardiology (DGK), and the German Heart Foundation (Deutsche Herzstiftung e.V.). Dr Sandner received research grants from Vascular Graft Solutions. Dr Schunkert received research grants from AstraZeneca.

Funding Information:
The TiCAB trial was sponsored by Deutsches Herzzentrum München, Germany. Financial support for the trial was provided by AstraZeneca. Dr von Scheidt received funding from the Clinician Scientist Excellence Program of the German Center for Cardiovascular Research (DZHK), the German Society of Cardiology (DGK), and the German Heart Foundation (Deutsche Herzstiftung e.V.). Dr Sandner received research grants from Vascular Graft Solutions. Dr Schunkert received research grants from Astra Zeneca.

Publisher Copyright:
© 2022 The Society of Thoracic Surgeons

Fingerprint

Dive into the research topics of 'Ticagrelor or Aspirin After Coronary Artery Bypass in Patients With Chronic Kidney Disease'. Together they form a unique fingerprint.

Cite this